With uncertainty continuing to surround the ongoing pandemic, Biointellisense Inc. has revealed that it is teaming up with the American College of Cardiology (ACC) to advance remote patient monitoring programs for cardiac care. In addition, the ACC plans to offer the company's Biobutton COVID-19 Screening Solution at the 70th Annual Scientific Session & Expo, scheduled for May 15-17 in Atlanta.
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: GAO shoots down Draeger appeal of VA bid; Three EU nations join stockpile program.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbott, Clearmind Biomedical, Medtronic, Organogenesis.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Amgen, Astrazeneca, BBS-Bioactive Bone Substitutes, Biotricity, Bitmedical, Bristol-Myers Squibb, Broad Institute, Bruker, Cardiofocus, GHGK, Global Medical Supply, Grail, Helius Medical Technologies, Helix, Histosonics, Illumina, Inovytec, Kura Oncology, Li-Cor Biosciences, Merck, Microport CRM, Microsoft, Milestone Scientific, Myriad Genetics, Pixcell Medical, Polarityte, Precision Biologic, Protom, Rakuten Medical, Roche, Seer, Triolab, Verily Life Sciences.
Keeping you up to date on recent developments in cardiology, including: MRI shows lower degrees of myocarditis in athletes who have recovered from COVID-19; Nanodroplets, ultrasound drills show promise with blood clots; Common blood pressure meds safe for those with COVID-19.
Cognitoss, a resorbable bone graft in development by Locate Bio Ltd., received U.S. FDA breakthrough device designation for treating chronic osteomyelitis, a progressive, inflammatory bone infection. The graft uses a new class of composite collagen product combined with a dual-phasic release of antibiotics to prevent reinfection.
TORONTO – Scan the literature on mental health technologies, and you’ll find treatment apps for everything from depression to addiction. What you won’t find, said Claude Hariton, vice president and chief scientific officer at Quebec City-based Diamentis Inc., are tools to diagnose mental diseases. It’s a gap the company hopes to fill with Retinal Signal Processing and Analysis (RSPA), a tool just accepted into the U.S. FDA’s breakthrough devices program that diagnoses mental diseases from retinal signals in the eye.
In recent years, Israel has proven to be a hot spot for med-tech innovation. The country boasts more than 1,500 companies in the health care and life sciences sectors, roughly 70% in medical devices and digital health. More than a hundred new companies focused on medical technology launch each year.
RSS
